Time to pop the champagne – 100,000 genomes have been reached. Well done Genomics England!
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
UC San Francisco scientists have figured out why some lung cancers become drug-resistant after initially responding to targeted therapies.
APP, the gene responsible for making beta-amyloid in the brain, may be able to reshuffle its own DNA, scientists from Sanford Burnham Prebys Medical Discovery Institute in California have claimed. This development could explain why most drugs to treat Alzheimer’s, which are designed to remove beta-amyloid protein build-ups in the brain, have proven ineffective in clinical trials.
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer’s disease, according to research that scientists say may pave the way to a clinical trial.
Pharmacogenetic tests are marketed as an aid to psychiatrists in selecting the antidepressant or antipsychotic medication that will work best in individual patients. But for most patients, these pharmacogenetic tests don’t provide much useful information.
STAT news have put together a great article assessing the need for health care systems to get on top of the payment issue quickly. Give it a read!
The Novartis CAR-T cell therapy, Kymriah (tisagenlecleucel), will be made available to patients under the age of 25 via the Cancer Drugs Fund.
If you’ve been part of the GeoMx DSP Technology Access Program, then you’ll already know why this is so exciting. If you haven’t heard about it yet, then you should make sure you’re sitting down – yes it really is that exciting.
The Science and Science Careers’ 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Independent US Food and Drug Administration (FDA) advisors unanimously backed Celltrion’s new Rituxan biosimilar recently, potentially allowing the company to threaten the sales dominance of Roche’s top drug.